Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of HM61713 in NSCLC Patients With EGFR Mutation

The main objective of this study is to evaluate the safety and tolerability of HM61713.

Study Overview

• Status: Completed
• Conditions: Non Small Cell Lung Cancer
• Intervention / Treatment: Drug: HM61713

Detailed Description

Besides the main objective, there are 3 other objectives as follows:

• To evaluate the anti-cancer effect of HM61713 in NSCLC patients with EGFR mutation
• To investigate the pharmacokinetic profile of HM61713 and its metabolites after oral administration
• To investigate biomarkers related to the safety and efficacy of HM61713

• Study Type: Interventional
• Enrollment (Actual): 273
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC
• Patients with EGFR mutation-positive tumor
• Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
• Estimated life expectancy of at least 12 weeks

• Subjects with adequate bone marrow (WBC ≥4,000/mm3, Platelet ≥100,000/mm3, Hemoglobin≥9.0g/dL, ANC≥1,500/mm3), renal (Creatinine≤1.5 mg/dl) and hepatic [aspartate aminotransferase (AST)/ alanine aminotransferase (ALT)/ alkaline phosphatase (ALP)≤3 x ULN, Total bilirubin ≤2.0 mg/dL] function. No significant heart and lung disease.

  ※ For subjects with a liver metastases, AST/ALT/ALP≤ 5 x ULN is allowed; and for subjects with bone marrow metastases, ALP≤ 5 x ULN is allowed

• Patients with amylase level ≤ 1.5 x ULN
• Subjects who have provided voluntary consent to participate in the study, and signed the written consent document

<Dose escalation part>

- Malignancy that has progressed after at least two prior chemotherapy regimens, including EGFR-TKI

<Expansion part 1>

• Patients with disease progression despite anticancer therapy with EGFR-TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib)
• Patients who have provided voluntary consent for collection of tumor tissue taken and archived after the last anticancer therapy or collection of new tissue specimen and signed the written consent document

<Expansion part 2> & <Phase 2>

• Patients with disease progression despite anticancer therapy with EGFR TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR mutation selective inhibitor, the same class of drug as investigational drug in this study)
• T790M mutation-positive confirmed in tissue collected after PD is confirmed during or after the last anticancer therapy
• At least one measurable target lesion allowing repeated measurement according to RECIST ver1.1 as of screening

<Phase 1 Expansion part 3>

• Patients with disease progression despite anticancer therapy with EGFR TKI (e.g., erlotinib, gefitinib, neratinib, afatinib, dacomitinib) (Except treatment with EGFR mutation selective inhibitor, the same class of drug as investigational drug in this study)
• T790M mutation-negative confirmed in tissue collected after progressive disease (PD) is confirmed during or after the last anticancer therapy
• At least one measurable target lesion allowing repeated measurement according to RECIST ver1.1 as of screening

Exclusion Criteria:

• Hematologic malignancies
• Symptomatic or uncontrolled central nervous system metastases
• Interstitial lung disease, including pulmonary fibrosis
• LVEF < 40% or NYHA Class III or IV heart failure
• History of pancreatitis
• History or current evidence, of any psychiatric or congenital disorder, including dementia or epilepsy
• Compromised organ function, infection or allergy
• Pregnant or breast-feeding women, or women of child-bearing potential who do not use an appropriate method of contraception (male patients should also use an appropriate method of contraception during the study period)
• Patients who had received other investigational product within 30 days prior to screening

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HM61713	Drug: HM61713; BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops; Other Names: Olmutinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Safety and tolerability	Dose limiting Toxicity will be evaluated on Day 24 during Cycle 1

Collaborators and Investigators

• Sponsor: Hanmi Pharmaceutical Company Limited
• Investigators: Principal Investigator: Dong-Wan Kim, MD PhD, Seoul National University Hospital

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (Actual): August 1, 2017
• Study Completion (Actual): August 1, 2017

Study Registration Dates

• First Submitted: April 26, 2012
• First Submitted That Met QC Criteria: April 27, 2012
• First Posted (Estimate): April 30, 2012

Study Record Updates

• Last Update Posted (Actual): April 24, 2018
• Last Update Submitted That Met QC Criteria: April 23, 2018
• Last Verified: April 1, 2018

More Information

Terms related to this study

• Keywords: NSCLC; Phase II; EGFR-TKI; HM61713; olmutinib
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
• Other Study ID Numbers: HM-EMSI-101